The Specialty Drug Pipeline Will Break Small Group Stop Loss Pricing Within Five Years

The prevailing view in the stop loss market is that specialty drug cost pressure is manageable. Carriers have tools: attachment point increases, laser provisions at renewal, specialty drug carve-out policies, and premium rate adjustments. The market has absorbed cost shocks before. HIV protease inhibitors in the 1990s and hepatitis C treatments in the mid-2010s arrived with prices that seemed impossible and were absorbed. The market adapts. Stop loss carriers are sophisticated actuarial businesses. The specialty drug pipeline is a known risk, and known risks get priced.

The uncomfortable possibility is that the specialty drug pipeline of 2024 through 2030 is structurally different from prior drug cost shocks in ways that disrupt the repricing logic. The pipeline is not producing one or two drugs at extraordinary cost; it is producing dozens of therapies, each capable of generating claims that exceed the annual specific stop loss attachment points of small group plans, arriving simultaneously and targeting an expanding range of conditions. The actuarial assumption that carriers can price against this risk requires a predictable distribution of who will need these therapies and when. That distribution, across groups of 5 to 25 employees, is not calculable. The carriers will not absorb the cost. They will exit the smallest market segments, or reprice to levels that render level funded economically nonviable for groups under 15 lives. The timeline for that market failure is five years, measured from when the approvals of 2023 through 2025 translate into covered claims for small group plans.

The Pipeline Is Not One Drug. It Is a Category.

#

Prior drug cost shocks were concentrated. Sovaldi (sofosbuvir) arrived in 2013 at $84,000 for a treatment course for hepatitis C. The cost was shocking and the political pressure was intense. But Sovaldi and its successors cured a defined patient population with a defined condition. The prevalence of hepatitis C in the insured population was estimable. Carriers could model the exposure, increase premiums, and wait for the prevalence to decline as cures removed the patient pool.

The cell and gene therapy pipeline operates differently. The FDA approved seven novel cell and gene therapies in 2023, setting a record. In 2024, seven more were approved with three additional expanded indications. The FDA has more than 500 gene therapy candidates in clinical trials, with the Alliance for Regenerative Medicine projecting 10 to 20 approvals annually by 2025 and beyond. Each approval targets a condition. Each condition has a patient population. Each patient population includes some number of people in employer-sponsored health plans. And each therapy carries a price point that would, in a small group plan without stop loss, be the plan’s financial event of the decade.

The price points published in recent approvals illustrate the scale. Hemgenix (etranacogene dezaparvovec), approved for hemophilia B in 2022, was priced at $3.5 million per treatment. Casgevy (exagamglogene autotemcel), approved for sickle cell disease in December 2023, was priced at $2.2 million. Lyfgenia (lovotibeglogene autotemcel), approved for sickle cell disease in the same month, was priced at $3.1 million. Lenmeldy (atidarsagene autotemcel), approved for metachromatic leukodystrophy in 2024, entered the U.S. market at $4.25 million, the highest-priced drug in the world at the time of its approval. These are single-treatment costs, not annual costs.

A PMC analysis of FDA approvals from 2000 through 2024 found that 57 percent of the 897 novel drugs approved in that period were classified as specialty drugs, and that specialty approvals increased at approximately 3 percent per year. Since 2012, specialty drugs have accounted for more than half of all FDA drug approvals in every year. Among the 50 novel drugs approved in 2025, 74 percent went through expedited regulatory pathways, largely targeting high-acuity conditions in specialty care. The pipeline is not slowing. It is accelerating.

The Repricing Has Already Started and Is Not Keeping Up

#

The stop loss market has been responding to specialty drug cost pressure through premium increases for several years. The Aegis Risk Medical Stop-Loss Premium Survey, which covers more than 1,200 plan sponsors, documents the trajectory. Stop loss premiums increased 16 percent from 2021 to 2023. From 2022 through 2024, annualized increases in individual stop loss premiums ranged from 10.4 percent at a $100,000 deductible to 13.8 percent at a $750,000 deductible, according to the 2024 Aegis Risk survey. From 2024 to 2025, increases ranged from 8.8 percent to 10.5 percent depending on deductible level, with Aegis noting that the longer-term trend of 9.9 to 12.1 percent may better reflect 2026 renewal pricing given the claims experience Cigna, Voya, and Sun Life reported for the fourth quarter of 2024.

Segal’s stop loss database, drawing on nearly 240 health plans for its 2024 report, found an average stop loss premium increase of 9.4 percent. For plans that maintained consistent specific stop loss benefit levels without increasing deductibles, the average increase was 11.5 percent. A year earlier, Segal’s 2023 dataset reported an 8.4 percent average increase, with groups maintaining benefit levels experiencing 13.4 percent premium growth.

Sun Life’s 2024 Stop-Loss Research Report found that million-dollar claims rose 8 percent on a claims-per-million-covered-employees basis from 2023 to 2024, and were up 50 percent over the prior four years. The average cost of cardiovascular disease treatment rose 33 percent in a single year, significantly above the general medical cost inflation rate of 5.9 percent.

These are the repricing signals of a market that is chasing cost trend from behind. The carriers are increasing premiums by 10 to 14 percent annually while the drug pipeline is adding new high-cost therapies at a rate that actuarial models for small groups cannot keep up with. The repricing is incremental. The pipeline is categorical. When the approved therapies of 2023 through 2025 convert from pipeline approvals into covered patient claims within small group plans, the next three to five years of stop loss renewal pricing will reflect both the individual claims that have already occurred and the actuarial adjustments for the known pipeline. The Aegis 2025 survey documents that 49 percent of respondents reported a claimant exceeding $1 million in paid claims in the last two policy years. Three million dollar claims are, in Aegis principal Ryan Siemers’s phrasing, “the new $1 million claim.”

How This Breaks Small Group Specifically

#

The leveraged trend mechanism is the mechanical explanation for why the specialty drug pipeline affects small group stop loss disproportionately compared to large group plans.

Leveraged trend describes what happens to stop loss premium when the underlying cost of a catastrophic claim increases while the specific attachment point stays constant. A plan with a $100,000 specific attachment point pays the first $100,000 of any individual member’s annual claims. If the stop loss attachment point covers everything above $100,000, and a specialty drug that cost $500,000 last year now costs $600,000, the plan’s retained cost is unchanged (the first $100,000), but the stop loss carrier’s liability increased from $400,000 to $500,000, a 25 percent increase. The stop loss premium must increase by more than the underlying medical trend to compensate for this leverage effect.

For large self-funded plans with hundreds or thousands of covered members, the statistical distribution of catastrophic claims is predictable enough for actuarial pricing. The carrier knows approximately what percentage of a 5,000-member population will generate claims above the attachment point in a given year, adjusted for age, condition prevalence, and geographic factors. The premium is an actuarially grounded prediction.

For a small group plan with 10 to 15 members, the question is not “what percentage of our population will generate a catastrophic claim” but “will any single member generate a catastrophic claim this year.” At 10 members, the probability that at least one member will have a child diagnosed with a condition now treatable by a $2 million gene therapy, or will themselves be diagnosed with a cancer now treated with a $600,000 CAR-T therapy, is small in any given year. But the expected cost to the stop loss carrier if that event occurs is enormous relative to the premium collected. The carrier cannot spread this risk across the 10-member group. The carrier has to load the premium with enough uncertainty margin to compensate for the binary nature of the exposure, which makes the premium unaffordable, or accept a margin that is too thin for the tail risk, which makes the carrier exit the segment.

The 2025 Aegis survey notes that 60 or more new cell and gene therapies are expected to be approved by 2030. The stop loss market, which currently has stop loss ceded premium exceeding $10 billion as of 2023 (per the Rough Notes analysis), is responding by building carve-out specialty drug and gene therapy policies. Interest in specialty prescription drug and gene therapy carve-out policies was reported by 21 percent of Aegis survey respondents in 2025. That carve-out interest signals that the main stop loss market is already treating the specialty drug pipeline as a risk category it wants to isolate from standard stop loss pricing, rather than absorb within it.

The Segment Exit Scenario

#

When stop loss carriers cannot price a segment profitably, they exit. They do not announce exit. They simply stop quoting, or quote at premiums that amount to the same thing.

The historical precedents are in other casualty and property insurance markets. Flood insurance in coastal zones became uninsurable for private carriers and required government intervention through the National Flood Insurance Program. Homeowners insurance in wildfire-prone California has seen major carrier exits since 2023, with State Farm and Allstate withdrawing from the new business market before regulators and the state’s FAIR plan absorbed the residual exposure. Medical malpractice insurance in specific specialties has experienced periodic hard markets where carriers exit rather than price in exposure they cannot model.

The small group stop loss market is approaching a similar dynamic, but from a specific direction: the drug pipeline creates a category of claims that have unlimited upside (a $4.25 million drug is not the last expensive drug; it is the current record, which will be broken), that target conditions that can affect any member regardless of prior health status (sickle cell disease affects young adults; spinal muscular atrophy affects newborns; some gene therapies treat conditions not diagnosable at underwriting), and that are medically legitimate and legally covered by plan documents that did not explicitly exclude them when written.

Carriers are responding with carve-outs, as noted above, and with contract language that excludes specific therapies or limits coverage to defined benefit levels. QBE North America reported only three gene therapy claims between 2022 and 2024 across nearly 2 million covered lives, indicating that the current frequency is low. But the pipeline approved since 2022 has not yet translated fully into routine prescribing. The gap between FDA approval and patient access in employer plans typically runs 18 to 36 months, reflecting formulary decisions, prior authorization processes, and patient-physician awareness. The claims from 2023 through 2025 approvals will arrive in stop loss portfolios in 2025 through 2028. That is the five-year window.

What Remains for the Smallest Groups

#

If stop loss pricing for groups under 15 lives becomes unavailable or uneconomic within five years, level funded loses its foundational risk management mechanism for the smallest viable segment of its market.

The alternatives for a 10-person employer are not attractive in comparison. Fully insured small group coverage continues to exist but has been losing market share to level funded precisely because its pricing has been less transparent and its cost trend has been higher than level funded for healthy small groups. Returning to fully insured does not solve the specialty drug cost problem; fully insured premiums reflect the same cost trend that is driving stop loss increases, embedded in the community-rated or experience-rated premium rather than explicit attachment point mechanics.

ICHRA transfers the employer’s coverage obligation to the individual market, where the ACA’s risk pooling across all marketplace enrollees in a rating area provides the actuarial stability that a 10-person group cannot. For the smallest employers, ICHRA may be the most rational exit from a deteriorating level funded market for micro-groups, which connects to the convergence thesis in TOS.08. The specialty drug pipeline does not merely change stop loss pricing in isolation; it accelerates the structural shift away from group coverage for the smallest employers by making the stop loss mechanism that makes group coverage viable for small employers increasingly untenable.

The carriers will not announce that small group stop loss is broken. They will raise prices until employers voluntarily exit, then characterize the exit as employer preference rather than market failure. The employers who remain will pay premiums that are increasingly disconnected from their own group’s risk profile and increasingly reflective of the actuarial uncertainty that makes small group stop loss underwriting a guess dressed as an estimate.

The five-year timeline is not a prediction of the year the market fails. It is an estimate of when the trend becomes visible enough that the industry stops describing it as a pricing cycle and starts describing it as a structural problem. That moment arrives when renewal quotes for sub-15-life groups begin to include explicit gene therapy exclusions as standard contract language, when carriers require specialty drug carve-outs as a condition of quoting, and when the median employer in that size band faces renewal premium increases that exceed what the market will sustain. These signals of segment exit in process are already present in the structure of current carrier behavior. What remains is for them to become prevalent enough that the industry names them honestly.